Brandtree

Coloplast: brands it owns and its ownership tree

Coloplast (CPH: COLO B) is a publicly listed company headquartered in Humlebæk, Denmark that owns 8 consumer brands across 2 categories.[1]

Coloplast is a Danish medical device company headquartered in Humlebæk. Its 2024/25 annual report groups its business into Chronic Care (ostomy, continence, voice and respiratory) and Acute Care (wound and tissue repair, interventional urology). Coloplast Holding ApS holds 29.49% of the share capital and 51.36% of the votes, and B shares trade on Nasdaq Copenhagen. It acquired Atos Medical in 2022 and Kerecis in 2023.

Company facts

Legal name
Coloplast A/S
Type
publicly listed company · see all publicly listed company owners
Headquarters
🇩🇰 Humlebæk, Denmark
Tickers
CPH: COLO B
Website
www.coloplast.com
Last verified
· 1 sources

Coloplast in numbers

Everything Coloplast owns

Controlling ownership as of . Brands grouped under the entity that owns them; large groups are collapsed.

Everything Coloplast owns Tree of 8 brands under Coloplast. Coloplast Biatain Comfeel Conveen Kerecis Luja Peristeen Self-Cath SpeediCath

Full-screen interactive tree → · Download as infographic

Brand portfolio by category

Full portfolio, 8 brands, with sources →

Recent changes to this record

All changes →

Frequently asked questions

What brands does Coloplast own?

Coloplast owns 8 consumer brands tracked here, including Biatain, SpeediCath, Kerecis, Conveen, Self-Cath and Peristeen.

Is Coloplast a Danish company?

Yes. Coloplast is headquartered in Humlebæk, Denmark.

Who owns Coloplast?

Coloplast is a publicly listed company owned by its shareholders; it trades as COLO B on the CPH.

Sources (1) & corrections

Last verified . Every ownership fact above is backed by one of these primary documents. Numbers in brackets in the text refer to this list.

  1. [1] Coloplast Annual Report 2024/25 — Coloplast A/S, Annual report, published 4 November 2025; retrieved 3 October 2026.

Report a correction Opens a pre-filled GitHub issue. See our corrections policy.